Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation

Annals of the New York Academy of Sciences

Volumn 1348, Issue 1, 2015, Pages 116-123

  Alayev, Anya ^a   Berger, Sara Malka ^a   Holz, Marina K ^a,b,c  

^a YESHIVA UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

autophagy; breast cancer; lymphangioleiomyomatosis; rapamycin; resveratrol; TOR

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; RESVERATROL;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; LUNG METASTASIS; LYMPHANGIOLEIOMYOMATOSIS; MASS SPECTROMETRY; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

EID: 84937468530     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12829     Document Type: Article

References (80)

1. Vastano, B.C. et al. 2000. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J. Agric. Food Chem. 48: 253–256.
2. Renaud, S. & M. de Lorgeril. 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523–1526.
3. Tome-Carneiro, J. et al. 2012. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 110: 356–363.
4. Jang, M. et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218–220.
5. Lu, J. et al. 2001. Resveratrol analog, 3,4,5,4’-tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis 22: 321–328.
6. Ogas, T., T.P. Kondratyuk & J.M. Pezzuto. 2013. Resveratrol analogs: promising chemopreventive agents. Ann. N. Y. Acad. Sci. 1290: 21–29.
7. Kang, S.Y. et al. 2014. Biosynthesis of methylated resveratrol analogs through the construction of an artificial biosynthetic pathway in E. coli. BMC Biotechnol. 14: 67.
8. Park, S.H. et al. 2015. Pterostilbene, an active constituent of blueberries, stimulates nitric oxide production via activation of endothelial nitric oxide synthase in human umbilical vein endothelial cells. Plant Foods Hum. Nutr. (Epub ahead of print).
9. Morris, V.L. et al. 2015. Anti-tumor properties of cis-resveratrol methylated analogs in metastatic mouse melanoma cells. Mol. Cell. Biochem. 402: 83–91.
10. Baur, J.A. et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337–342.
11. Kang, L. et al. 2010. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: relative to inhibition of inflammatory responses. Biochimie 92: 789–796.
12. Lagouge, M. et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109–1122.
13. Pearson, K.J. et al. 2008. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8: 157–168.
14. Tsai, S.H., S.Y. Lin-Shiau & J.K. Lin. 1999. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126: 673–680.
15. Benitez, D.A. et al. 2009. Regulation of cell survival by resveratrol involves inhibition of NF kappa B-regulated gene expression in prostate cancer cells. Prostate 69: 1045–1054.
16. Sun, A.Y. et al. 2010. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 41: 375–383.
17. Agarwal, B. & J.A. Baur. 2011. Resveratrol and life extension. Ann. N. Y. Acad. Sci. 1215: 138–143.
18. Szkudelska, K. & T. Szkudelski. 2010. Resveratrol, obesity and diabetes. Eur. J. Pharmacol. 635: 1–8.
19. Mobasheri, A. & M. Shakibaei. 2013. Osteogenic effects of resveratrol in vitro: potential for the prevention and treatment of osteoporosis. Ann. N. Y. Acad. Sci. 1290: 59–66.
20. Quincozes-Santos, A. et al. 2013. Resveratrol protects C6 astrocyte cell line against hydrogen peroxide-induced oxidative stress through heme oxygenase 1. PLoS One 8: e64372.
21. Alayev, A. & M.K. Holz. 2013. mTOR signaling for biological control and cancer. J. Cell. Physiol. 228: 1658–1664.
22. Jeno, P. et al. 1988. Identification and characterization of a mitogen-activated S6 kinase. Proc. Natl. Acad. Sci. U.S.A. 85: 406–410.
23. Gurusamy, N. et al. 2010. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc. Res. 86: 103–112.
24. Holz, M.K. & J. Blenis. 2005. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J. Biol. Chem. 280: 26089–26093.
25. Gwinn, D.M. et al. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30: 214–226.
26. Puissant, A. et al. 2010. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res. 70: 1042–1052.
27. Armour, S.M. et al. 2009. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging 1: 515–528.
28. He, X. et al. 2011. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett. 301: 168–176.
29. Manning, B.D. et al. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10: 151–162.
30. Chen, Q. et al. 2010. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5: e15288.
31. Peterson, T.R. et al. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873–886.
32. Liu, M. et al. 2010. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J. Biol. Chem. 285: 36387–36394.
33. Park, S.J. et al. 2012. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421–433.
34. Kubota, S. et al. 2011. Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation. Invest. Ophthalmol. Vis. Sci. 52: 9142–9148.
35. Hubbard, B.P. et al. 2013. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339: 1216–1219.
36. Shima, H. et al. 1998. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17: 6649–6659.
37. Beher, D. et al. 2009. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74: 619–624.
38. Pacholec, M. et al. 2010. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 285: 8340–8351.
39. Hou, X. et al. 2008. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 283: 20015–20026.
40. DeSantis, C. et al. 2011. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol. Biomarkers Prev. 20: 733–739.
41. DeSantis, C. et al. 2011. Breast cancer statistics, 2011. CA Cancer J. Clin. 61: 409–418.
42. Bowers, J.L. et al. 2000. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141: 3657–3667.
43. Waite, K.A., M.R. Sinden & C. Eng. 2005. Phytoestrogen exposure elevates PTEN levels. Hum. Mol. Genet. 14: 1457–1463.
44. Narayanan, N.K. et al. 2009. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 125: 1–8.
45. Provinciali, M. et al. 2005. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int. J. Cancer 115: 36–45.
46. Garvin, S., K. Ollinger & C. Dabrosin. 2006. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231: 113–122.
47. Bove, K., D.W. Lincoln & M.F. Tsan. 2002. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 291: 1001–1005.
48. Ghosh, H.S., M. McBurney & P.D. Robbins. 2010. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One 5: e9199.
49. Sheth, S. et al. 2012. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One 7: e51655.
50. Rubinsztein, D.C., P. Codogno & B. Levine. 2012. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. 11: 709–730.
51. Bjorkoy, G. et al. 2009. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 452: 181–197.
52. Chen, N. & V. Karantza-Wadsworth. 2009. Role and regulation of autophagy in cancer. Biochim. Biophys. Acta 1793: 1516–1523.
53. White, E. & R.S. DiPaola. 2009. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res. 15: 5308–5316.
54. Liang, X.H. et al. 1999. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402: 672–676.
55. Morselli, E. et al. 2009. Anti- and pro-tumor functions of autophagy. Biochim. Biophys. Acta 1793: 1524–1532.
56. Degenhardt, K. et al. 2006. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 51–64.
57. Karantza-Wadsworth, V. et al. 2007. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Develop. 21: 1621–1635.
58. Samaddar, J.S. et al. 2008. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol. Cancer Ther. 7: 2977–2987.
59. Liang, J. et al. 2007. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9: 218–224.
60. Esclatine, A., M. Chaumorcel & P. Codogno. 2009. Macroautophagy signaling and regulation. Curr. Top. Microbiol. Immunol. 335: 33–70.
61. Chang, Y.Y. & T.P. Neufeld. 2010. Autophagy takes flight in Drosophila. FEBS Lett. 584: 1342–1349.
62. Zeng, X. & T.J. Kinsella. 2008. Mammalian target of rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy. Cancer Res. 68: 2384–2390.
63. Eisenberg-Lerner, A. et al. 2009. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 16: 966–975.
64. Sun, W. L. et al. 2011. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 7: 1035–1044.
65. Widlund, A.L., J.A. Baur & O. Vang. 2013. mTOR: more targets of resveratrol? Exp. Rev. Mol. Med. 15: e10.
66. Carter, L.G., J.A. D'Orazio & K.J. Pearson. 2014. Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer 21: R209–R225.
67. Yu, C. et al. 2002. Human, rat, and mouse metabolism of resveratrol. Pharm. Res. 19: 1907–1914.
68. Soleas, G.J. et al. 2001. Absorption of trans-resveratrol in rats. Methods Enzymol. 335: 145–154.
69. Dias, S.J. et al. 2013. Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation and growth in prostate cancer xenografts. Prostate 73: 1135–1146.
70. Henske, E.P. & F.X. McCormack. 2012. Lymphangioleiomyomatosis—a wolf in sheep's clothing. J. Clin. Invest. 122: 3807–3816.
71. Logginidou, H. et al. 2000. Frequent estrogen and progesterone receptor immunoreactivity in renal angiomyolipomas from women with pulmonary lymphangioleiomyomatosis. Chest 117: 25–30.
72. Matsui, K. et al. 2000. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am. J. Respir. Crit. Care Med. 161: 1002–1009.
73. McCormack, F.X. 2008. Lymphangioleiomyomatosis: a clinical update. Chest 133: 507–516.
74. Goncharova, E.A. et al. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277: 30958–30967.
75. Alayev, A. et al. 2014. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells. Cell Cycle 13: 371–382.
76. Ellis, M. 2004. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9(Suppl 3): 20–26.
77. Miller, T.W., J.M. Balko & C.L. Arteaga. 2011. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 29: 4452–4461.
78. Alayev, A. et al. 2014. The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells. J. Cell. Biochem. 116:450–457.
79. Alayev, A. et al. 2014. Phosphoproteomics Reveals Resveratrol-dependent Inhibition of Akt/mTORC1/S6K1 Signaling. J. Proteome Res. 13:5734–5742.
80. Alayev, A. et al. 2015. The combination of rapamycin and resveratrol causes apoptosis and reduces growth of TSC2-deficient xenograft tumors. Am. J. Respir. Cell Mol. Biol. (Epub ahead of print).